1. Electrochemotherapy (ECT) in treatment of mucosal head and neck tumors. An international network for sharing practices on ECT (InspECT) study group report.
- Author
-
Bertino G, Minuti M, Groselj A, Jamsek C, Silvestri B, Carpene S, Matteucci P, Riva G, Pecorari G, Mascherini M, Kjær Lønkvist C, Muir T, Kunte C, de Terlizzi F, and Sersa G
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Laryngeal Neoplasms therapy, Laryngeal Neoplasms drug therapy, Laryngeal Neoplasms pathology, Treatment Outcome, Aged, 80 and over, Pharyngeal Neoplasms therapy, Pharyngeal Neoplasms drug therapy, Pharyngeal Neoplasms pathology, Mouth Neoplasms drug therapy, Mouth Neoplasms therapy, Mouth Neoplasms pathology, Neoplasm Recurrence, Local, Europe, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Electrochemotherapy methods, Head and Neck Neoplasms therapy, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms pathology
- Abstract
The aim of this multicenter study was to evaluate the effectiveness and safety of electrochemotherapy (ECT) for the treatment of mucosal tumors in the head and neck. A total of 71 patients with 84 nodules of different histologies in the oral cavity, pharynx and larynx treated by ECT were evaluated. The data were collected from the InspECT database from 10 participating centers throughout Europe. Primary and recurrent/secondary tumors of different histologies were treated. The overall response rate was 65 %, with a 33 % complete response rate with limited side effects. The response rates of the primary and secondary tumors were not different. However, smaller tumors responded better than tumors larger than 3 cm in diameter. Furthermore, the tumors that were treated with curative intent responded significantly better than those treated with palliative intent. This study demonstrated the feasibility, safety and effectiveness of ECT in a larger cohort of patients with mucosal lesions in the head and neck region. Based on the available data, ECT can be used for the treatment of recurrent and, in some cases, primary mucosal tumors located in the oral cavity, larynx, and pharynx. A better response was obtained in patients with smaller primary tumors treated with curative intent., Competing Interests: Declaration of competing interest Francesca de Terlizzi is an IGEA employer. No other authors have conflicts of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF